Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,541

Britain’s young teens will be vaccinated — but with a single dose.

London: Britain’s chief medical officers have said that vaccinating young teenagers against COVID-19 is justified when their mental health and education are taken into account.

Minors aged between 12 and 15 in England will be offered just a single dose of Pfizer or Moderna beginning next week, with more research ordered into whether a second dose should be given, as is currently administered to those aged 16 and above.

The decision by the CMOs brings the UK partly into line with countries like Australia, the United States, Israel and many European nations including France, which are already offering the jab to minors.

Read more | >

Automation will drag on at the normal pace. 2025 i think will be the key year, where Human Level hands could turn up on the humanoid robots, and an early phase of Human Level AI turns up; if those 2 things happen automation of jobs will really start to move fast.

Ask for a roast beef sandwich at an Arby’s drive-thru east of Los Angeles and you may be talking to Tori — an artificially intelligent voice assistant that will take your order and send it to the line cooks.

“It doesn’t call sick,” says Amir Siddiqi, whose family installed the AI voice at its Arby’s franchise this year in Ontario, California. “It doesn’t get corona. And the reliability of it is great.”

The pandemic didn’t just threaten Americans’ health when it slammed the U.S. in 2020 — it may also have posed a long-term threat to many of their jobs. Faced with worker shortages and higher labor costs, companies are starting to automate service sector jobs that economists once considered safe, assuming that machines couldn’t easily provide the human contact they believed customers would demand.

Read more | >

Israeli scientists are harnessing the “destructive” qualities of allergy-causing cells, as part of a bold attempt to pioneer a new immunotherapy for fighting cancer. A research team from Tel Aviv University has found that eosinophils, white blood cells that induce allergies, significantly reduce the growth of human tumors in vitro, and mouse tumors in the body. Nine days after mice were injected with eosinophils, the overall size of tumors per mouse averaged half that of mice who weren’t injected.

Tumors in mice lost half their size when injected with eosinophils, best known for inducing allergies; promising results also seen in human tumor cells in vitro.

Read more | >

Crypto currency, fast grants, publishing sucess and failures, intellectual property, all good.

Around $26 million in grant funding has just been made available for scientific research that can improve our understanding and control of human aging thanks to the donations of supporters such as Vitalik Buterin. Will this launch solve aging? The grants, known as Impetus Grants, are specifically designed to have immediate impact. Scientists can request up to $500,000, and decisions will be made within three weeks.

Impetus Grants exemplify the increasing crossover between the blockchain and cryptocurrency communities and the longevity community. The founding donor was Juan Benet of Filecoin, and he was joined by Mt. Gox creator and Stellar co-founder Jed McCaleb. Well known longevity founder and cryptocurrency pioneer Vitalik Buterin has also donated around $5 million dollars worth of Ethereum, a cryptocurrency which he helped to create.

Impetus Grants are a project of The Longevity Apprenticeship managed by Martin Borch Jensen, the chief scientific officer of Gordian Biotechnology. Gordian claims to have created the first in vivo therapeutic screening platform to radically improve drug development for complex diseases of aging.

This style of funding was inspired by COVID-19 Fast Grants, which were designed to be “faster sources of emergency science funding during the pandemic.” The first round of those grants were given out within 48 hours, with the review of subsequent applications happening within two weeks.

Continue reading “ Million to Solve Aging? Crypto-boosted Impetus Grants Launch!” | >

Anna’s guest at Women’s Radio was Dr Ian C E Hale I’m an Autistic person. It’s an indivisible part of who I am as an individual.

Annas guest at Women’s Radio was Dr Ian C E Hale ‘All things Autism will be aired at 1pm and 1am every day this week. Please see www.womensradiostation.com

Dr Ian C E Hale shared:

To be clear … it’s important to put my book and other work into context by knowing a little of their origins. I’m an Autistic person. It’s an indivisible part of who I am as an individual; it informs, goads and limits every thought and act of my life-but I refuse to let it define me. I’m a sportsman, poet, photographer, medical scientist and more-but first and foremost, a human being, with the same fears, hopes, weaknesses and feelings as everyone else.

Read more | >

BioNTech, the company that partnered with Pfizer to develop a COVID-19 vaccine, is now testing whether mRNA can be used to treat cancer.

Messenger RNA (mRNA) vaccines work by tricking our bodies into producing a small part of a virus. For the Pfizer–BioNTech COVID-19 vaccine, this involved isolating the spike protein of SARS-CoV-2 (the virus that causes COVID-19). This protrudes from the outer surface of the virus and is used to latch onto specific cells in your body, infecting them and causing more copies of the virus to be made. Researchers obtained the spike protein’s RNA, then created mRNA based on these molecular instructions.

Once injected, the mRNA vaccine will instruct cells to build spike proteins in large volumes – not the virus itself, just the spike protein. This is enough to kickstart our immune response, training the body to recognise the spike protein, without making us sick. B-cells (also known as lymphocytes) can last for months or years and will “remember” the spike protein, making Y-shaped proteins called antibodies to destroy any SARS-CoV-2 encountered in the future.

Read more | >

While is seems like the majority of the longevity space is currently overly captivated by the Aubrey de Grey/SENS debacle, the U.S. National Academy of Sciences, Healthy Longevity Global Innovator Summit is now beginning — Most interestingly, former R&D Head at PepsiCo, Dr. Mehmoud Khan, will be speaking in his new role as CEO of the Hevolution Foundation; a potential multi-billion $$$ initiative with a longevity angle — Everyone should keep their eye on this one…

The National Academy of Medicine (NAM) will hold its inaugural Healthy Longevity Global Innovator Summit in September 2,021 with support from Johnson and Johnson Innovation and The John A. Hartford Foundation. The event will be virtual and held over three days, September 13 14, and 22 and feature an immersive, interactive digital venue with unique opportunities to engage and connect.

The Innovator Summit will honor the 154 international Healthy Longevity Catalyst Awardees from 2020 and bring together industry leaders, academics, researchers, scientists, and entrepreneurs whose work contributes to the field of healthy longevity. Attendees will learn about the early-stage, award-winning innovations, hear from leaders in the field of healthy longevity, and take advantage of various opportunities to interact directly with other attendees, with a view to fostering interdisciplinary and cross-sector collaboration.

The event will feature remarks from the President of the National Academy of Medicine, Dr. Victor Dzau, and Catalyst Award Sponsors, Dr. William Hait, Global Head of Johnson & Johnson External Innovation, and Dr. Terry Fulmer, President of the John A. Hartford Foundation. Visionary keynote speakers will share insights into launching biotechnology start-ups and opportunities for groundbreaking science in the field of longevity. Participants will also be able to enjoy a robust selection of breakout sessions and the chance to network with Catalyst Award winners, researchers, venture capitalists, and more in one-on-one and small group settings.

Read more | >

As we age, our bones become thinner, we suffer fractures more often, and bone-diseases such as osteoporosis are more likely to occur. One responsible mechanism involves the impaired function of the bone-marrow stem cells, which are required for the maintenance of bone integrity. Researchers from the Max Planck Institute for Biology of Ageing and CECAD Cluster of Excellence for Ageing Research at the University of Cologne have now shown that the reduced stem cell function upon aging is due to changes in their epigenome. They were able to reverse these changes in isolated stem cells by adding acetate. This fountain of youth for the epigenome could become important for the treatment of diseases such as osteoporosis.

Aging Researchers have been looking at epigenetics as a cause of aging processes for some time. Epigenetics looks at changes in and chromosomes that do not alter the sequence of the genes themselves, but do affect their activity. One possibility is changes in proteins called histones, which package the DNA in our cells and thus control access to DNA. The Cologne research group of Peter Tessarz has now studied the epigenome of mesenchymal . These stem cells are found in marrow and can give rise to different types of cells such as cartilage, bone and fat cells.

Read more | >

With all that said, it’s natural for humans to crave and eat limited amounts of sugar. After going through all the research, here’s what I am doing for myself.

For example, foods high in fructose stimulate ghrelin while suppressing leptin—hormones responsible for hunger and satiety. Sugar can promote chronic hyperglycemia, which can both lead to weight gain and is another risk for diabetes. And sugary drinks, especially, are tied directly to obesity.

Sugar and aging: a bad combination (so what should we do?)

People looking to stay young for a long time should limit their sugar consumption. While how added sugar works in the body isn’t simple or predictable, there are literally thousands of studies tying added sugar to diseases of aging.

Read more | >